Back

Glycemic variability and coronary plaque progression in statin-treated type 2 diabetic patients with coronary artery disease: a prespecified sub-analysis of the OPTIMAL Randomized Controlled Trial

28 August 2026 (15:10 - 15:20)
Organised by: Logo
Congress Presentation Part of: Diabetes and acute coronary syndrome Diabetes and the Heart ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Anthony Salib

Austin Hospital, Melbourne (Australia)

5 More presentations in this session

Presentation thumbnail
Impact of diabetes mellitus on clinical outcomes of stepwise dual antiplatelet therapy de-escalation after drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial
Doctor C. Gao (Hefei, CN)
Presentation thumbnail
Contemporary characteristics and management of patients with myocardial infarction and diabetes in Europe: Insights from EuroHeart
Doctor A. Haider (Vasteras, SE)
Abstract Slides
Presentation thumbnail
SCORE2-diabetes predicts coronary complexity assessed by SYNTAX score in diabetic patients with first myocardial infarction
Doctor B. Spataru (Bucharest, RO)
Abstract Slides
Presentation thumbnail
Diabetes is associated with increased myocardial infarction risk regardless of coronary artery disease status: a 15-year follow-up study
Ms A. Odgaard (Aarhus, DK)
Abstract Slides
Presentation thumbnail
Associations of stress hyperglycemia ratio with rapid non-culprit lesion progression and clinical outcomes in acute coronary syndrome: a multicenter cohort study according to diabetes status
Doctor P. Wang (Beijing, CN)
Abstract Slides

Access the full session

Session thumbnail
Diabetes and acute coronary syndrome
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 15:10 CET
You may be interested in
thumbnail
Congress Presentation
High levels of small dense LDL cholesterol potentiate the risk of poor glycemic management for long-term prognosis in patients with stable coronary artery disease
1 September 2025
thumbnail
Congress Presentation
The significance of 24h blood pressure variability improvement regarding target organ damage indices three years after medical treatment initiation in essential hypertension
31 August 2019
thumbnail
Congress Presentation
Apolipoprotein B and the regression of lipidic plaque in statin-treated type 2 DM patients with coronary artery disease: the pre-specified sub-analysis from the OPTIMAL randomized controlled trial
30 August 2024
thumbnail
Congress Presentation
Non-invasive continuous glucose monitoring in patients without diabetes: use in cardiovascular prevention - a systematic review
3 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources